TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/08/2025
Voltar para busca
Dado oficial do USPTO
CYTUNE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
42
Atualização mais recente
10/08/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42, 44
Data de depósito
17/12/2020
Data de registro
20/09/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
20/09/2022
Última transação
10/08/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
3
Tipo de titular
99
Localização do titular
Nantes, FR
Examinador
ZARICK, DIANA
Unidade examinadora
N80
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the stylized wording "CYTUNE" in black; to the left is an arrowhead shaped figure in oblong lines with the top in magenta and the bottom in orange.
Titulares e representantes
Titulares
Cytune Pharma S.A.S.
Representantes
Shane Rumbaugh Rumbaugh Law PLLC
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceuticalsmedical and veterinary preparations for the prevention and treatment of neoplasiatumorscancer and infectious diseases; anticancer preparations; antitumor drugs in the nature of tumor suppressing agents; vaccines; anticancer vaccines; pharmaceutical preparations for the treatment of neoplasiatumorscancer and infectious diseasespeptidesrecombinant proteinsantibodiesantibody derivativesantibody-drug conjugatesnucleotides and nucleotide analogs for medical and veterinary purposes; biological preparations for the treatment of neoplasiatumorscancer and infectious diseases for medical and veterinary purposes; cellular preparations for the treatment of neoplasiatumorscancer and infectious diseases for medical and veterinary purposes; radiopharmaceutical preparations for the treatment of neoplasiatumors and cancer for diagnosticmedical and veterinary use; pharmaceutical preparations for the treatment of autoimmune diseases and infectious diseases; diagnostic agentspreparations and test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detectionneoplasiatumorscancer and infectious diseases for medical and veterinary purposes; drug delivery agents; adjuvants for medical use; dietetic substances adapted for medical use
Classe 42
Scientific and technological servicesresearch and design in the field of biotechnological and pharmaceutical research and development; industrial analysis and research services in the field of biotechnological and pharmaceutical research and development; scientific research for medical and veterinary purposes; scientific research and development for medical and veterinary purposes in the area of cancerous diseasesautoimmune diseases and infectious diseases; pharmaceutical drug development services; conducting clinical trials for others; scientific preclinical and clinical research in the field of prevention and treatment of neoplasiatumorscancer and infectious diseases; scientific preclinical and clinical research in the fields of biologics and chemotherapy; analysis of toxicology and mode of action of biological and chemicals and combinations on animals; pharmaceutical and biological product researchdevelopmentsafety testingquality control testing services for others; scientific research and development for diagnostic purposes; computer-aided diagnostic testing services in the nature of computer diagnostic services; design and development of computer software and databases; design and development of computer software and databases for logisticssupply chain management and laboratory management
Classe 44
Medical services; medical diagnostic services
Publicações
Histórico de despachos e eventos da marca no USPTO.
42 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/08/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/08/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
16/02/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
16/02/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
16/02/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
20/09/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
20/09/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/07/2022
PUBO
PUBLISHED FOR OPPOSITION
05/07/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
15/06/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
26/05/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/05/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/05/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
25/05/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/02/2022
GNRT
NON-FINAL ACTION E-MAILED
07/02/2022
CNRT
NON-FINAL ACTION WRITTEN
07/02/2022
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
31/01/2022
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
11/01/2022
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
28/12/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/12/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
27/12/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
27/12/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
27/12/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
27/12/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/12/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/12/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
18/12/2021
ALIE
ASSIGNED TO LIE
15/12/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/12/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
30/11/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
30/11/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
30/11/2021
DOCK
ASSIGNED TO EXAMINER
29/09/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
18/06/2021
GNRT
NON-FINAL ACTION E-MAILED
18/06/2021
CNRT
NON-FINAL ACTION WRITTEN
18/06/2021
DOCK
ASSIGNED TO EXAMINER
11/06/2021
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
27/02/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
26/02/2021
NWAP
NEW APPLICATION ENTERED
21/12/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CYTUNE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.